One private equity–backed company owns every methadone clinic in Montana

Understanding the Opioid Crisis

The opioid epidemic has escalated into one of the most pressing public health emergencies in the United States. According to the National Institute on Drug Abuse, over 120 people die daily from opioid overdoses, reflecting a crisis that has evolved over decades. For individuals like Amber Titus, who has journeyed through the labyrinthine healthcare system to access methadone treatment, the struggles are all too real.

Methadone is a long-established medication used to treat opioid use disorder (OUD). It works by alleviating withdrawal symptoms and reducing drug cravings, thus significantly lowering the risk of overdose. However, despite its efficacy, only 22% of individuals diagnosed with OUD receive methadone treatment. Access issues are particularly acute in rural areas, where transportation and clinic hours can present formidable barriers.

A Day in the Life

Amber Titus, a resident of Bisbee Junction, Arizona, exemplifies the challenges faced by many seeking treatment. Her commitment to traveling 30 miles for her methadone dose three times a week underscores the daunting reality many patients encounter. With strict rules about attendance and punctuality, missing a dose can have serious repercussions. In a recent instance, after losing her car in an accident, Titus struggled to secure timely rides to the clinic, resulting in missed doses.

Such experiences highlight the systemic inefficiencies in the healthcare system that are exacerbated by the monopolistic nature of methadone clinics across the country, especially in states like Montana, where one company controls all local clinics.

The Role of Private Equity

In recent years, private equity firms have made significant inroads into the healthcare sector, acquiring a vast number of methadone clinics. This shift raises critical questions about the motivations behind these acquisitions and their impact on patient care. Research conducted by economists at Brown University and other institutions indicates that despite acquiring over one-third of methadone clinics nationwide, private equity investments have not increased the availability of methadone treatment or led to the establishment of new facilities.

Private equity firms are attracted to the methadone treatment sector due to its guaranteed demand and regulatory structure. Opioid Treatment Programs (OTPs) are tightly regulated, creating a government-sanctioned monopoly where patients have limited options for receiving treatment. The firms benefit from controlling these clinics in regions where they can dictate the terms of access to life-saving medications.

Market Control and Access Issues

The strategies employed by private equity firms resemble those found in other industries. By acquiring existing clinics instead of building new ones, they can quickly dominate local markets. For instance, research findings indicate that within two years of a private equity acquisition, the acquiring firm typically controls about 67% of the local methadone treatment market. In some counties, a single firm has seized control of all available clinics.

The implications of such concentrated ownership are dire. With fewer clinics to choose from, patients may face longer travel times and decreased access to care. In Montana, for example, all methadone clinics are owned by Community Medical Services (CMS), a private equity-backed company. This lack of competition could discourage the expansion of services and lead to stagnant treatment options.

The Case of Community Medical Services

CMS provides a pertinent case study of private equity’s influence in the methadone treatment landscape. Originally operating 14 clinics in four states, CMS has expanded to 79 clinics across 14 states, including four in Montana. Despite this growth, local residents like Amber Titus find their access to treatment unchanged.

Nick Stavros, CEO of CMS, has indicated that while the company is expanding, the lack of new clinics in Montana is largely due to financial constraints. Building a new clinic is estimated to cost around $2.5 million, a figure that can be prohibitive for rural areas. Thus, despite the potential for growth, many regions remain underserved.

Arguments for and Against Private Equity

Supporters of private equity involvement in methadone treatment argue that these firms can help fill gaps left by public funding shortfalls. A study has shown that clinics acquired by private equity firms are more likely to accept Medicare and Medicaid, possibly due to the resources that larger chains can provide.

However, critics contend that the benefits of private equity come with caveats. For example, while patient volume at buprenorphine facilities increased after acquisition, the continuity of care — a crucial factor in preventing relapse — declined. This raises alarming questions about the quality of care being provided, particularly for methadone treatment, which requires consistent patient engagement.

Legislative Efforts to Reform Access

The ongoing debate surrounding private equity’s role in addiction treatment is intertwined with legislative efforts aimed at reforming access to methadone. The Modernizing Opioid Treatment Access Act 2.0, introduced in 2023, seeks to allow regular physicians to prescribe methadone and enable pharmacies to dispense it. This would dismantle the long-standing restrictions limiting methadone distribution to OTPs.

This bill has gained traction among patient advocacy organizations and medical societies, reflecting a growing consensus on the need for reform. However, opposition arises from the American Association for the Treatment of Opioid Dependence (AATOD), which argues that expanding access could lead to increased risks of diversion and overdose. Their position underscores the complexities of balancing accessibility with patient safety.

The Way Forward

As Congress weighs the implications of the Modernizing Opioid Treatment Access Act, the stakes for individuals like Amber Titus could not be higher. For those living in rural areas, the challenges of accessing methadone treatment can be life-altering. Legislative changes that facilitate more flexible prescribing and dispensing practices could ease some of these burdens, but resistance from entrenched interests complicates the path forward.

The growing presence of private equity in healthcare, particularly in areas as sensitive as addiction treatment, calls for intense scrutiny. While investment can bring about improvements, the primary aim must remain patient care and accessibility. Without a balanced approach that prioritizes patient needs, the healthcare system risks perpetuating an already dire situation for those struggling with opioid addiction.

Conclusion

In summary, the concentration of methadone clinics under private equity ownership raises critical questions about patient access and quality of care. Amber Titus's story is a microcosm of the broader challenges faced by many seeking treatment in a system dominated by financial interests. As the opioid crisis continues to evolve, it is essential to adopt policies that enhance access to treatment, ensure the quality of care, and ultimately prioritize the health and well-being of patients across the nation. The path forward will require collaboration, reform, and a commitment to addressing the root causes of the addiction crisis, especially in underserved areas like Montana.